---
title: Validate Italian non motor fluctuations
nct_id: NCT06406374
status: RECRUITING
sponsor: A.O.U. Città della Salute e della Scienza
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06406374"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06406374"
last_fetched: "2026-05-10T14:02:47.916Z"
source: "Parkinson's Pathways (curated)"
---
# Validate Italian non motor fluctuations

**Goal (in five words):** Validate Italian non motor fluctuations

**Official Title:** Italian Translation and Validation of the Non-Motor Fluctuation Assessment (NoMoFA) Questionnaire.

**Trial ID:** [NCT06406374](https://clinicaltrials.gov/study/NCT06406374)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** A.O.U. Città della Salute e della Scienza
- **Target Enrollment:** 200 participants
- **Start Date:** 2023-04-26
- **Completion Date:** 2024-06-10
- **Conditions:** Parkinson's Disease

## Summary For Families

The goal is to create and check an Italian version of the NoMoFA questionnaire so clinicians can reliably track non-motor fluctuations in Parkinson's, like changes in mood, thinking, sleep, and autonomic symptoms that come and go with medication cycles. The approach is observational, translating and validating the questionnaire by having eligible patients complete it alongside standard measures to confirm it actually detects these on/off non-motor problems and is easy to use in clinic. They are looking for Italian-speaking people diagnosed with idiopathic Parkinson's by MDS criteria who have MMSE scores above 25, report symptom fluctuations on the WOQ-19 (score ≥2), have had stable Parkinson medications for at least three months, and do not have atypical parkinsonism or very advanced disease (Hoehn and Yahr >4). No drug or device is being tested; about 200 participants will be enrolled.

## Eligibility

- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Diagnosis of idiopathic Parkinson\'s disease according to the 2015 Movement Disorders Society (MDS) criteria (Postuma et al. Mov Dis, 2015);
* Italian speaker;
* Mini-mental state examinations (MMSE) score \>25;
* Presence of symptoms fluctuations, as per a Wearing-off questionnaire 19 (WOQ-19) score\>=2;
* Stable antiparkinsonian medications for at least three months
* Ability to provide informed consent.

Exclusion Criteria:

* Atypical Parkinsonian syndrome
* H\&Y\>4
* Patients under legal protection
```

## Locations (1)

- Dipartimento di Neuroscienze e Salute Mentale SC Neurologia 2U, Torino, TO, Italy _(44.8886, 11.9914)_
  - Carlo Alberto Artusi, MD, PhD — (CONTACT) — 011 6709366 — carloalberto.artusi@unito.it

## Central Contacts

- Carlo Alberto Artusi, MD, PhD — (CONTACT) — +390116709366 — carloalberto.artusi@unito.it

---

*Canonical: https://parkinsonspathways.com/trial/NCT06406374*  
*HTML version: https://parkinsonspathways.com/trial/NCT06406374*  
*Source data: https://clinicaltrials.gov/study/NCT06406374*